Rivia, a Zurich-based startup, has announced that it has raised €13 million to boost the development of AI agents for clinical trial management. This funding follows a previous round of €3 million, used to unify fragmented data related to clinical trials.

Objective: Efficiency in clinical trials

Clinical trials are complex processes that require efficient management of large amounts of information. Rivia's goal is to develop AI agents capable of automating and improving the operational management of these trials, reducing the associated times and costs.

Funding context

This new funding will allow Rivia to accelerate the development and implementation of its technology, with the aim of transforming the way clinical trials are conducted.